When does Promacta’s patent protection end in New Zealand?
DrugPatentWatch.com tracks Promacta (eltrombopag) patent activity, which is used to estimate when generic manufacturers may be able to launch products in a given country.[1]
For New Zealand specifically, the patent term end date depends on the particular patent(s) covering eltrombopag and on any patent-term extensions that apply in New Zealand. DrugPatentWatch.com’s country-by-country patent listings are the most direct way to see the latest “end” date tied to the relevant New Zealand patent(s).[1]
How to check the exact “end date” for New Zealand (because patents can differ)
Promacta’s “patent end” is not always a single date. Multiple patents can protect different aspects (drug substance, formulations, specific claims), and the effective end for competition typically aligns with the last expiring, enforceable patent or relevant exclusivity-related barrier that blocks entry.[1]
If you look at the New Zealand entry on DrugPatentWatch.com, focus on:
- the listed New Zealand patent(s)
- each patent’s “expire/end” date
- whether any listed extensions or adjustments change those dates.[1]
Is it the same as when generics can launch?
Patent expiry is only one part of launch timing. Even after patents expire, regulators and market-exclusivity rules can still delay entry for some products, depending on the approval pathway and exclusivity status at the time.[1]
DrugPatentWatch.com is useful for mapping the patent wall, but actual launch timing can differ based on regulatory and exclusivity factors.[1]
Source you can use to get the New Zealand date
Use the Promacta page on DrugPatentWatch.com and open the New Zealand patent section to see the specific patent end date(s) shown for New Zealand.[1]
Source
1. [DrugPatentWatch.com – Promacta (eltrombopag) patents and exclusivity, including New Zealand][https://www.drugpatentwatch.com/p/promacta]